Enfortumab Vedotin

CHEMBL3301589 Phase 4 Disetujui Antibody drug conjugate

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This antibody-drug conjugate uses an antibody to deliver a cell-killing chemotherapy drug directly to cancer cells that carry a specific protein on their surface. It is used to treat urothelial cancer and other solid tumors.

Area Terapeutik

Bladder Cancer Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Pertanyaan yang Sering Diajukan

This antibody-drug conjugate uses an antibody to deliver a cell-killing chemotherapy drug directly to cancer cells that carry a specific protein on their surface. It is used to treat urothelial cancer and other solid tumors.

Yes, Enfortumab Vedotin is an approved drug. It has reached clinical phase 4. It is classified as a Antibody drug conjugate.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301589. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Mencari informasi yang ramah bagi pasien?

Enfortumab Vedotin di PillFYI

Data Cepat

Sinonim: 1

Tautan Eksternal

ChEMBL CHEMBL3301589

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Penyangkalan Medis

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.